NCT06257225

Brief Summary

To address the gap of knowledge in comparing between the bone augmentation outcomes with or without tacks for membrane stabilization

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
22

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Feb 2024

Shorter than P25 for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 5, 2024

Completed
8 days until next milestone

First Posted

Study publicly available on registry

February 13, 2024

Completed
2 days until next milestone

Study Start

First participant enrolled

February 15, 2024

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 30, 2024

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2024

Completed
Last Updated

February 13, 2024

Status Verified

February 1, 2024

Enrollment Period

1 month

First QC Date

February 5, 2024

Last Update Submit

February 5, 2024

Conditions

Keywords

GBRTacs

Outcome Measures

Primary Outcomes (1)

  • Horizontal bone gain assessed radiographically (mm)

    Using CBCT

    Baseline , 4 month

Secondary Outcomes (6)

  • Horizontal bone gain assessed clinically (mm)

    Baseline , 4 month

  • Amount of Pain

    7 days

  • Amount of Pain

    7 days

  • Patient satisfaction

    4 month

  • Surgical Time

    During Surgery

  • +1 more secondary outcomes

Study Arms (2)

Patient showing horizontal defect and treated with GBR stabilized with Tacs

ACTIVE COMPARATOR

Fixation

Procedure: Guided Bone regeneration

Patient showing horizontal defect and treated with GBR stabilized with no Tacs

EXPERIMENTAL

No Fixation

Procedure: Guided Bone regeneration

Interventions

After local anesthesia, a crestal incision will be performed followed by full-thickness mucoperiosteal flap elevation Flap advancement will be attained through periosteal scoring of the buccal; The resorbable collagen membrane (Bio Gide, Geistlich AG) will be trimmed to the defect size. Xenograft (Bio-Oss) together with scrapped autogenous bone will be mixed and placed at the surgical site. The membrane will positioned over the graft and tucked into the lingual flap. Patient allocation concealment will be broken and the patients will be randomly assigned into two groups Patients receiving horizontal bone augmentation with resorbable collagen membrane stabilized with no tacks. The first layer will be closed with horizontal mattress sutures placed 4 mm from the incision line, and single interrupted sutures are used to close the edges of the flap. Vertical incisions are closed using single interrupted sutures and mattress suture should remain in place for at least 2 to 3 weeks

Patient showing horizontal defect and treated with GBR stabilized with TacsPatient showing horizontal defect and treated with GBR stabilized with no Tacs

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with at least 1 missing tooth in the posterior mandibular area Patients with an age above 18 years Systemically healthy patients
  • Healed alveolar ridge for implant placement with:
  • Deficient buccolingual dimension ( ≤5mm)
  • Sufficient vertical height (≥ 10 mm)
  • Sufficient mesio-distal width (≥ 6.5 mm) Inter-arch space ≥ 7 mm to allow space for implant-supported crown Presence of neighboring and opposing dentition Soft tissue phenotype with keratinized tissue width (KTW) (≥2 mm) and gingival thickness (≥2 mm) Good oral hygiene Cooperative patients who accepted the trial follow up period and sign the informed consen

You may not qualify if:

  • Systemic diseases or medications that might affect bone metabolism, increase surgical risk or complicate post-operative healing Untreated periodontal diseases History of radiation therapy to the head and neck Heavy smokers (≥ 10 cigarettes per day) Pregnant or lactating females Alcoholism or drug abuse Psychiatric problems Patients with signs of acute infection related to the area of interest

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Spondylocostal Dysostosis 4, Autosomal Dominant

Study Officials

  • Hani ElNahass, PhD

    Cairo University

    PRINCIPAL INVESTIGATOR
  • Omnia Tawfik, PhD

    Cairo University

    STUDY CHAIR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Periodontology

Study Record Dates

First Submitted

February 5, 2024

First Posted

February 13, 2024

Study Start

February 15, 2024

Primary Completion

March 30, 2024

Study Completion

June 30, 2024

Last Updated

February 13, 2024

Record last verified: 2024-02